Back to Search
ANTHONY BOTTINI, MD
MD
Neurological Surgery Physician
NPI: 1265422927Individual
Specialties, Licenses & Credentials
Neurological Surgery PhysicianPrimary
Neurological Surgery
Code: 207T00000X
29932(MN)
Research & Publications (20)
Increased activation of Iba1+ microglia in pediatric epilepsy patients with Rasmussen's encephalitis compared with cortical dysplasia and tuberous sclerosis complex.
PMID 19285133·Neurobiol Dis·2009
8-other
The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib.
PMID 19417138·Cancer Res·2009
8-other
Immunomodulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients.
PMID 19188178·Clin Cancer Res·2009
8-other
Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer.
PMID 19064988·J Clin Oncol·2009
3-trial
Changes of bone turnover markers and serum PTH after night or morning administration of zoledronic acid in breast cancer patients with bone metastases.
PMID 18506177·Br J Cancer·2008
2-rct
Presurgical systemic treatment of nonmetastatic breast cancer: facts and open questions.
PMID 18997125·Oncologist·2008
6-review
Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era.
PMID 18952558·Clin Breast Cancer·2008
4-observational
Optimisation of the post-validation process: the report and recommendations of ECVAM Workshop 67.
PMID 18662098·Altern Lab Anim·2008
7-preclinical
Down-regulation of phosphatidylinositol 3'-kinase/AKT/molecular target of rapamycin metabolic pathway by primary letrozole-based therapy in human breast cancer.
PMID 18451231·Clin Cancer Res·2008
2-rct
Variations along the 24-hour cycle of circulating osteoprotegerin and soluble RANKL: a rhythmometric analysis.
PMID 17703272·Osteoporos Int·2008
8-other
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer.
PMID 17687648·Breast Cancer Res Treat·2008
3-trial
Regulation of hepatocyte growth factor activator inhibitor 2 by hypoxia in breast cancer.
PMID 17255277·Clin Cancer Res·2007
2-rct
The circadian rhythm of biochemical markers of bone resorption is normally synchronized in breast cancer patients with bone lytic metastases independently of tumor load.
PMID 16935041·Bone·2007
8-other
Patients with advanced stage breast carcinoma immunoreactive to biotinylated Herceptin are most likely to benefit from trastuzumab-based therapy: an hypothesis-generating study.
PMID 17785760·Ann Oncol·2007
8-other
Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients.
PMID 16877730·J Clin Oncol·2006
3-trial
Role of carbonic anhydrase IX expression in prediction of the efficacy and outcome of primary epirubicin/tamoxifen therapy for breast cancer.
PMID 16954440·Endocr Relat Cancer·2006
8-other
Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer.
PMID 16899602·Clin Cancer Res·2006
2-rct
Prognostic significance of changes in CA 15-3 serum levels during chemotherapy in metastatic breast cancer patients.
PMID 16670941·Breast Cancer Res Treat·2006
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 3931 LOUISIANA AVE S
ST LOUIS PARK, MN 55426 - Phone
- (952) 993-3123
Quick Facts
- NPI
- 1265422927
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile